Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical guideline SEOM: cancer of unknown primary site.
Collado Martín R, García Palomo A, de la Cruz Merino L, Borrega García P, Barón Duarte FJ; Spanish Society for Medical Oncology. Collado Martín R, et al. Among authors: de la cruz merino l. Clin Transl Oncol. 2014 Dec;16(12):1091-7. doi: 10.1007/s12094-014-1244-0. Epub 2014 Nov 13. Clin Transl Oncol. 2014. PMID: 25392080 Free PMC article.
Knowing the myeloid-derived suppressor cells: Another enemy of sarcomas patients.
García-Domínguez DJ, Sánchez-Margalet V, de la Cruz-Merino L, Hontecillas-Prieto L. García-Domínguez DJ, et al. Among authors: de la cruz merino l. Int Rev Cell Mol Biol. 2023;375:93-116. doi: 10.1016/bs.ircmb.2022.11.003. Epub 2023 Jan 11. Int Rev Cell Mol Biol. 2023. PMID: 36967155
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
Dummer R, Queirolo P, Gerard Duhard P, Hu Y, Wang D, de Azevedo SJ, Robert C, Ascierto PA, Chiarion-Sileni V, Pronzato P, Spagnolo F, Mujika Eizmendi K, Liszkay G, de la Cruz Merino L, Tawbi H. Dummer R, et al. Among authors: de la cruz merino l, de azevedo sj. Lancet Oncol. 2023 Dec;24(12):e461-e471. doi: 10.1016/S1470-2045(23)00334-0. Epub 2023 Jul 14. Lancet Oncol. 2023. PMID: 37459873
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.
Piulats JM, Watkins C, Costa-García M, Del Carpio L, Piperno-Neumann S, Rutkowski P, Hassel JC, Espinosa E, de la Cruz-Merino L, Ochsenreither S, Shoushtari AN, Orloff M, Salama AKS, Goodall HM, Baurain JF, Nathan P. Piulats JM, et al. Among authors: de la cruz merino l. Ann Oncol. 2024 Mar;35(3):317-326. doi: 10.1016/j.annonc.2023.11.013. Epub 2023 Dec 2. Ann Oncol. 2024. PMID: 38048850 Free article. Clinical Trial.
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial.
Tibau A, Martínez MT, Ramos M, De La Cruz-Merino L, Santaballa A, O'Connor M, Martínez-Jañez N, Moreno F, Fernández I, Virizuela JA, Alarcón J, de La Haba-Rodríguez J, Sánchez-Rovira P, Albacar CR, Bueno Muiño C, Kelly C, Casas M, Bezares S, Rosell L, Albanell J. Tibau A, et al. Among authors: de la haba rodriguez j, de la cruz merino l. Ther Adv Med Oncol. 2023 Jan 19;15:17588359221148921. doi: 10.1177/17588359221148921. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36743520 Free PMC article.
Obesity and Risk for Lymphoma: Possible Role of Leptin.
Jiménez-Cortegana C, Hontecillas-Prieto L, García-Domínguez DJ, Zapata F, Palazón-Carrión N, Sánchez-León ML, Tami M, Pérez-Pérez A, Sánchez-Jiménez F, Vilariño-García T, de la Cruz-Merino L, Sánchez-Margalet V. Jiménez-Cortegana C, et al. Among authors: de la cruz merino l. Int J Mol Sci. 2022 Dec 8;23(24):15530. doi: 10.3390/ijms232415530. Int J Mol Sci. 2022. PMID: 36555171 Free PMC article. Review.
Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies.
Sánchez-Molina S, Figuerola-Bou E, Sánchez-Margalet V, de la Cruz-Merino L, Mora J, de Álava Casado E, García-Domínguez DJ, Hontecillas-Prieto L. Sánchez-Molina S, et al. Among authors: de la cruz merino l, de alava casado e. Cancers (Basel). 2022 Nov 7;14(21):5473. doi: 10.3390/cancers14215473. Cancers (Basel). 2022. PMID: 36358891 Free PMC article. Review.
Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response.
Lejeune M, Reverté L, Sauras E, Gallardo N, Bosch R, Roso A, Petit A, Peg V, Riu F, García-Fontgivell J, Ibáñez J, Relea F, Vieites B, Bor C, de la Cruz-Merino L, Arenas M, Rodriguez V, Galera J, Korzynska A, Belhomme P, Plancoulaine B, Álvaro T, López C. Lejeune M, et al. Among authors: de la cruz merino l. Cancers (Basel). 2023 Jan 18;15(3):597. doi: 10.3390/cancers15030597. Cancers (Basel). 2023. PMID: 36765559 Free PMC article.
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
Neven P, Fasching PA, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Zarate JP, Wang Y, Chakravartty A, Wang C, Slamon DJ. Neven P, et al. Among authors: de la cruz merino l, de laurentiis m. Breast Cancer Res. 2023 Aug 31;25(1):103. doi: 10.1186/s13058-023-01701-9. Breast Cancer Res. 2023. PMID: 37653397 Free PMC article. Clinical Trial.
119 results